ENVALITH
ネクセラファーマ株式会社 logo

Nxera Pharma Co., Ltd.

4565・Prime Market・Pharmaceuticals

Official website
ネクセラファーマ株式会社 logo
Nxera Pharma Co., Ltd.4565

Business

Nxera Pharma Co., Ltd. (formerly Sosei Group) is a Japan-originated biopharmaceutical company with its proprietary GPCR structure-based drug discovery platform, the NxWave™ Platform. Its UK subsidiary, Nxera Pharma UK Limited, handles drug discovery and preclinical development, while its Japan and South Korea subsidiaries handle clinical development and sales. The company markets Pivlaz® (Clazosentan Sodium), a treatment for cerebral vasospasm, and Quviviq® (Daridorexant), a treatment for insomnia, in Japan, and also earns milestone and royalty income through multiple drug discovery collaborations with major global pharmaceutical companies such as Neurocrine Biosciences, AbbVie, and Eli Lilly. The company holds a pipeline of over 30 programs targeting neurological disorders, psychiatric and neurological disorders, metabolic diseases, and immune diseases, and has set a 2030 vision of revenue exceeding ¥50.0 billion and an operating margin of 30% or more.

Business Model

Revenue is composed of three layers: sales of proprietary products in Japan (Pivlaz®), royalties from partners (Quviviq® and respiratory disease products), and upfront payments/milestones/deferred revenue recognition from drug discovery collaborations with major global pharmaceutical companies. In FY2025 (ending December 2025), revenue from marketed products was ¥20,136 million (68% of total), while research and development revenue was ¥9,479 million (32% of total). While the proportion of product sales is increasing, milestone income is highly variable, creating a structure in which period-to-period revenue levels are affected accordingly.

Company Strengths

The "NxWave™" Platform held by the UK subsidiary is established as a global leader in GPCR structure-based drug discovery. The company has realized multiple drug discovery collaborations with major global players such as Pfizer, Genentech, AbbVie, Eli Lilly, and Neurocrine, and holds a pipeline of over 30 programs. 89% of R&D expenses are attributable to UK activities, and this concentration of drug discovery capability is a source of competitive advantage.

Pivlaz® achieved stable growth of ¥13,511 million (up 6.8% year on year) in FY2025 (ending December 2025). Quviviq® recorded ¥4,327 million (up 223.9% year on year) driven by full-scale contribution following its December 2024 launch. Respiratory disease royalties of ¥2,169 million from Novartis have also continued steadily, forming a revenue base of ¥20,136 million in total from launched products.

Multiple collaborations with major pharmaceutical companies are progressing simultaneously, including with Neurocrine (muscarinic receptor agonist, Phase 3 trial initiated), AbbVie (neurological disease, second milestone achieved), Eli Lilly (metabolic disease, development milestone achieved), and Centessa (OX2R agonist, favorable Phase 2 results), providing diversification of pipeline risk and opportunities for receiving major milestone payments in the future.

ENVALITH's Perspective

In Q1 FY2026, revenue was ¥11,256 million (up 69.4% year on year), operating profit was ¥3,244 million (versus a loss of ¥2,193 million in the same quarter of the previous year), and quarterly profit was ¥1,793 million (versus a loss of ¥760 million in the same quarter of the previous year), achieving a turnaround to profitability across all income indicators. Core operating profit also recovered sharply to ¥5,495 million from a loss in the same quarter of the previous year, confirming a clear reversal from the trend of widening losses that had continued through FY2025 (ending December 2025). However, results were significantly boosted by the special factor of seven milestone income items totaling ¥5,772 million, and it will be necessary to assess the sustainability of this trend over the full fiscal year.

The full-year FY2026 revenue guidance range spans ¥33,800 million to ¥48,800 million, a wide range of ¥15,000 million, with the upper end dependent on whether significant new upfront payments from new collaborations materialize. Because milestone income depends on the development progress and decision-making of partner companies, quarter-to-quarter volatility in results remains large, and the structural difficulty investors face in forecasting performance has not changed. The ¥5,772 million in milestone income recorded in Q1 FY2026 represents approximately 46% of the roughly ¥12,500 million in milestone income from existing partners assumed under the low end of the full-year guidance, achieved within a single quarter. While this progress is favorable, the pace of accumulation in the second half of the year warrants close monitoring.

Cash and cash equivalents at the end of Q1 FY2026 stood at ¥11,597 million, down ¥8,767 million from the previous fiscal year-end (¥20,365 million). The main factors were the acquisition of intangible assets (¥5,019 million) associated with the in-licensing of Vamorolone, repayment of long-term borrowings (¥1,450 million), and negative operating cash flow (¥1,654 million). Meanwhile, interest-bearing debt remains at a high level, with bonds payable of ¥26,156 million and borrowings (¥19,664 million non-current plus ¥5,798 million current). Although the company's cash-generating capacity has improved with core operating profit turning positive, continued close attention is needed regarding the level of the cash balance and the repayment schedule for interest-bearing debt.

Growth Strategy

Diversification of revenue through APAC expansion of Quviviq®, entry into rare disease with Vamorolone, and deepening of NxWave™ partnerships

Following favorable Phase 3 results in Korea, a marketing approval application was submitted in March 2026 (approval expected in 2027). In Taiwan, marketing approval was obtained in April 2026, with launch planned within 2026. Full-year FY2026 revenue in Japan is forecast at ¥5,000 million to ¥6,000 million (versus ¥4,327 million in FY2025 actual), reflecting continued growth.

In January 2026, entered into a development, manufacturing, and commercialization license agreement with Santhera for Japan, Korea, Australia, and New Zealand. Already approved and marketed in the US, EU, UK, and China, this late-stage product contributes to expanding the rare disease/specialty portfolio and diversifying future revenue sources.

Achieved seven milestones in Q1 FY2026 (¥5,772 million). From April 2026 onward, major milestones have arisen including Neurocrine's initiation of Phase 2 for NBI-1117570 (US$22.5 million), AbbVie (US$10 million), and Lilly (amount undisclosed). Full-year FY2026 milestone revenue from existing partners is expected at approximately ¥12,500 million.

Continued reduction of R&D expenses and SG&A expenses, achieving a combined cost reduction of ¥911 million year-on-year in Q1 FY2026. Full-year FY2026 cost reduction of approximately ¥3,500 million is expected. Restructuring costs of ¥469 million have been recorded, and mid- to long-term optimization of the cost structure is being pursued through the business restructuring program.

The rights to receive milestones and royalties for cleminorexton/ORX750, ORX142, and ORX489, which the Company co-created, will be maintained under the existing contract terms even after the acquisition by Lilly. Lilly's development capabilities and financial resources are expected to accelerate clinical development of the orexin 2 receptor agonist series and realize substantial future royalty income.

Last updated: July 17, 2026